Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 6/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25548770 | 0.96 | CXCR2 (0.45) | CXCR2SLC6A5TACR2KDM4EALDH1A1 | |
| SCHEMBL25548792 | 0.91 | CXCR2 (0.44) | CXCR2SLC6A5TACR2KDM4EALDH1A1 | |
| SCHEMBL25548758 | 0.89 | CNR2 (0.35) | CXCR2SLC6A5PDE2AITGB1 | |
| SCHEMBL23461920 | 0.88 | CXCR2 (0.59) | CXCR2SLC6A5KDM4EALDH1A1LMNA | |
| SCHEMBL23461432 | 0.87 | CXCR2 (0.46) | CXCR2SLC6A5TACR2KDM4EALDH1A1 | |
| SCHEMBL23460978 | 0.86 | CXCR2 (0.47) | CXCR2MAOA | |
| SCHEMBL23460906 | 0.86 | CXCR2 (0.42) | CXCR2SLC6A5TACR2KDM4EALDH1A1 | |
| SCHEMBL23461528 | 0.86 | CXCR2 (0.48) | CXCR2SLC6A5TACR2KDM4EALDH1A1 | |
| SCHEMBL23461082 | 0.84 | CXCR2 (0.60) | CXCR2SLC6A5KDM4EALDH1A1LMNA | |
| SCHEMBL25601485 | 0.84 | CXCR2 (0.42) | CXCR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885SLC6A5 641/4885TACR2 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.